<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01994265</url>
  </required_header>
  <id_info>
    <org_study_id>USP/UFMG 2013</org_study_id>
    <nct_id>NCT01994265</nct_id>
  </id_info>
  <brief_title>Cognitive Impairment Related to Atrial Fibrillation Prevention Trial</brief_title>
  <acronym>GIRAF</acronym>
  <official_title>Randomized Clinical Trial for the Prevention of Cognitive Impairment in Atrial Fibrillation Patients Treated With Dabigatran or Warfarin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federal University of Minas Gerais</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cognitive and functional decline observed in atrial fibrillation (AF) patients are related to
      thrombotic and/or cardioembolic events. Use of warfarin for the prevention of stroke in AF
      patients, despite effective, remains beyond desired levels because of interactions with food
      and fluctuations in blood levels. Because of a more stable anticoagulation state, Dabigatran
      may offer better protection against thrombotic phenomenon and, consequently, mitigate the
      process of cognitive and functional compromise.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective parallel study including two hundred atrial fibrillation patients
      &gt; 65 years old and scoring CHADS2VASc &gt; 1. Patients will be randomized to receive Warfarin
      (INR between 2 and 3) or Dabigatran (150 mg twice daily) for two years. After one year and at
      the end of the study, individuals will be evaluated regarding cognitive endpoints following
      the National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular
      Cognitive Impairment Harmonization Standards (Hachinski et al. Stroke 2006;37:2220-2241). The
      investigators will use the 60 minutes evaluation protocol complemented by the Montreal
      Cognitive Assessment (MoCA).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive impairment</measure>
    <time_frame>Two years</time_frame>
    <description>Cognitive impairment at two years, independently of stroke or other cerebrovascular events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with less important alteration in coagulation test as a Measure of Safety</measure>
    <time_frame>Two years</time_frame>
    <description>Comparison of thrombin generation test between the two treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with Warfarin once daily, taken at fast, to maintain INR between 2 and 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dabigatran 150 mg twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Warfarin once daily, at fast, targeting INR between 2 and 3</description>
    <arm_group_label>Warfarin</arm_group_label>
    <other_name>Marevan, Coumadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <arm_group_label>Dabigatran</arm_group_label>
    <other_name>Dabigatran 150 mg twice daily</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Atrial fibrillation

          -  CHA2DS2-VASc Score for Atrial Fibrillation Stroke Risk (CHADS2VASc) greater than 1

        Exclusion Criteria:

          -  Heart valve disease

          -  Previous Stroke or Transient ischemic attack

          -  Cognitive impairment or any severe neurological disorder

          -  Major surgery in the last 30 days

          -  Planned elective surgery in the next three months

          -  Intracranial, ocular, spinal, retroperitoneal, or articular bleeding without trauma.

          -  Gastrointestinal bleeding in the last 12 months

          -  Symptomatic gastric ulcer

          -  Hemorrhagic disease

          -  Use of thrombolytics

          -  Uncontrolled hypertension

          -  Active cancer

          -  Contraindication for Warfarin use

          -  Reversible causes of atrial fibrillation

          -  Creatinine clearance &lt; 30 ml/min

          -  Active endocarditis

          -  Active hepatitis

          -  Severe anemia

          -  Left ventricle ejection fraction &lt; 35%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Caramelli, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Institute, University of Sao Paulo, Brazil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno Caramelli, Professor</last_name>
    <phone>+551126615376</phone>
    <email>bcaramel@usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adriana F Pastana</last_name>
    <phone>+551126615376</phone>
    <email>adriana.pastana@usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Federal Univeristy of Minas Gerais</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30130100</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paulo Caramelli, Professor</last_name>
      <email>caramelli@ufmg.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heart Institute - University of São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Caramelli, Ph.D.</last_name>
      <phone>+551126615376</phone>
      <email>bcaramel@usp.br</email>
    </contact>
    <contact_backup>
      <last_name>Pai C Yu, Ph.D.</last_name>
      <phone>+551126615376</phone>
      <email>paichingyu@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bruno Caramelli, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pai C Yu, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2013</study_first_submitted>
  <study_first_submitted_qc>November 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Bruno Caramelli</investigator_full_name>
    <investigator_title>Associate Professor of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Cognition</keyword>
  <keyword>Cognitive impairment</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Dabigatran</keyword>
  <keyword>Warfarin</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

